3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
408
Rectal Neoplasms
152
Colonic Neoplasms
150
Pancreatic Neoplasms
114
Stomach Neoplasms
110
Neoplasm Metastasis
70
Esophageal Neoplasms
60
Esophageal Squamous Cell Carcinoma
33
Neoplasms
31
Adenocarcinoma Of Esophagus
27
Gastrointestinal Neoplasms
17
Cholangiocarcinoma
14
Biliary Tract Neoplasms
14
Gallbladder Neoplasms
12
Carcinoma, Hepatocellular
12
Adenocarcinoma
12
Colorectal Cancer Metastatic
11
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
11
Liver Neoplasms
10
Digestive System Neoplasms
10
Ovarian Neoplasms
9
Small Cell Lung Carcinoma
8
Locally Advanced Rectal Cancer
8
Intestinal Neoplasms
8
Bile Duct Neoplasms
8
Carcinoma
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Digestive System Diseases
6
Appendiceal Neoplasms
6
Interventions
pembrolizumab
4
Nivolumab
3
sintilimab
2
Oxaliplatin
2
Leucovorin
2
Fluorouracil
2
Bevacizumab
2
vicriviroc
1
trifluridine tipiracil drug combination
1
spartalizumab
1
relatlimab
1
regorafenib
1
epacadostat
1
dabrafenib
1
copanlisib
1
binimetinib
1
atezolizumab
1
Tiragolumab
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Fulvestrant
1
E7046
1
Cetuximab
1
Capecitabine
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Spinocerebellar Degenerations
×
Irinotecan
×
Gastrointestinal
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts